Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q1 2021 · 10-Q
Revenue$434.00K$434.00K−43.0% vs Q1 2020 Net Income-$37.76M-$37.76MN/M vs Q1 2020 EPS Diluted-$0.04-$0.04N/M vs Q1 2020 Operating Income-$37,889,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Free Cash Flowderived-$47,692,000N/M Margins · derivedOperating margin-8730.2%−4819.0 pt vs Q1 2020
Net margin-8701.2%−4999.8 pt vs Q1 2020
ended Mar 31, 2021 · filed May 6, 2021 · 36 d after period end